Human(ized) monoclonal antibodies in atopic patients – state of the art

Arzu Didem Yalcin; Kevser Onbasi; Rusen Uzun; Felix Herth; Philipp Albert Schnabel

doi:10.5114/ceji.2020.97909

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

2/2020
vol. 45

Send email

Copy url:

abstract:

Review paper

Human(ized) monoclonal antibodies in atopic patients – state of the art

Arzu Didem Yalcin

^{1, 2}

,

Kevser Onbasi

³

,

Rusen Uzun

⁴

,

Felix Herth

⁵

,

Philipp Albert Schnabel

⁶

Department of Internal Medicine, Allergy and Clinical Immunology, Genomics Research Center, Academia Sinica, Taipei, Taiwan
Department of Allergy and Clinical Immunology, Antalya Training and Research Hospital, University of Medical Science, Antalya, Turkey
Department of Internal Medicine, Allergy and Clinical Immunology, Dumlupinar University, Kütahya, Turkey
Department of Pulmonology, Antalya Training and Research Hospital, University of Medical Science, Antalya, Turkey
Department of Pulmonary and Critical Care Medicine, Thoraxklinik Translational Lung Research Center, University of Heidelberg, Heidelberg, Germany
Department of Pathology, University of Heidelberg, Heidelberg, Germany

Cent Eur J Immunol 2020; 45 (2): 195-201

DOI: https://doi.org/10.5114/ceji.2020.97909

Online publish date: 2020/07/27

View full text Get citation

PlumX metrics:

Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use . The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma.

keywords:

Human(ized) monoclonal antibodies in atopic patients – state of the art

Arzu Didem Yalcin 1, 2 , Kevser Onbasi 3 , Rusen Uzun 4 , Felix Herth 5 , Philipp Albert Schnabel 6

asthma, omalizumab, anti IL-5, humanized monoclonal antibodies

Arzu Didem Yalcin

^{1, 2}

,

Kevser Onbasi

³

,

Rusen Uzun

⁴

,

Felix Herth

⁵

,

Philipp Albert Schnabel

⁶